Please use this identifier to cite or link to this item: https://hdl.handle.net/10356/163208
Title: Robust delivery of RIG-I agonists using extracellular vesicles for anti-cancer immunotherapy
Authors: Peng, Boya
Nguyen, Trinh Mai
Jayasinghe, Migara Kavishka
Gao, Chang
Pham, Thach Tuan
Vu, Luyen Tien
Yeo, Eric Yew Meng
Yap, Gracemary
Wang, Lingzhi
Goh, Boon Cher
Tam, Wai Leong
Luo, Dahai
Le, Minh TN
Keywords: Science::Medicine
Issue Date: 2022
Source: Peng, B., Nguyen, T. M., Jayasinghe, M. K., Gao, C., Pham, T. T., Vu, L. T., Yeo, E. Y. M., Yap, G., Wang, L., Goh, B. C., Tam, W. L., Luo, D. & Le, M. T. (2022). Robust delivery of RIG-I agonists using extracellular vesicles for anti-cancer immunotherapy. Journal of Extracellular Vesicles, 11(4), e12187-. https://dx.doi.org/10.1002/jev2.12187
Project: NUHSRO/2019/076/STARTUP/02
NUHSRO/2020/108/T1/Seed-Mar/04
NMRC/OFIRG/0075/2018and OFIRG20nov-0049
Journal: Journal of Extracellular Vesicles
Abstract: The RIG-I pathway can be activated by RNA containing 5' triphosphate, leading to type I interferon release and immune activation. Hence, RIG-I agonists have been used to induce immune responses against cancer as potential immunotherapy. However, delivery of 5' triphosphorylated RNA molecules as RIG-I agonists to tumour cells in vivo is challenging due to the susceptibility of these molecules to degradation. In this study, we demonstrate the use of extracellular vesicles (EVs) from red blood cells (RBCs), which are highly amenable for RNA loading and taken up robustly by cancer cells, for RIG-I agonist delivery. We evaluate the anti-cancer activity of two novel RIG-I agonists, the immunomodulatory RNA (immRNA) with a unique secondary structure for efficient RIG-I activation, and a 5' triphosphorylated antisense oligonucleotide with dual function of RIG-I activation and miR-125b inhibition (3p-125b-ASO). We find that RBCEV-delivered immRNA and 3p-125b-ASO trigger the RIG-I pathway, and induce cell death in both mouse and human breast cancer cells. Furthermore, we observe a significant suppression of tumour growth coupled with increased immune cell infiltration mediated by the activation of RIG-I cascade after multiple intratumoral injections of RBCEVs loaded with immRNA or 3p-125b-ASO. Targeted delivery of immRNA using RBCEVs with EGFR-binding nanobody administrated via intrapulmonary delivery facilitates the accumulation of RBCEVs in metastatic cancer cells, leading to potent tumour-specific CD8+ T cells immune response. This contributes to prominent suppression of breast cancer metastasis in the lung. Hence, this study provides a new strategy for efficient RIG-I agonist delivery using RBCEVs for immunotherapy against cancer and cancer metastasis.
URI: https://hdl.handle.net/10356/163208
ISSN: 2001-3078
DOI: 10.1002/jev2.12187
Schools: Lee Kong Chian School of Medicine (LKCMedicine) 
Research Centres: NTU Institute of Structural Biology
Rights: © 2022 The Authors. Journal of Extracellular Vesicles published by Wiley Periodicals, LLC on behalf of the International Society for Extracellular Vesicles. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Fulltext Permission: open
Fulltext Availability: With Fulltext
Appears in Collections:LKCMedicine Journal Articles

SCOPUSTM   
Citations 20

25
Updated on Feb 23, 2024

Web of ScienceTM
Citations 20

20
Updated on Oct 26, 2023

Page view(s)

98
Updated on Feb 24, 2024

Download(s) 10

377
Updated on Feb 24, 2024

Google ScholarTM

Check

Altmetric


Plumx

Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.